Tech FDA approval

Supira Medical FDA Approval for pVAD Trial

Analysis based on 7 articles · First reported Apr 08, 2026 · Last updated Apr 08, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The FDA approval for Supira Medical's SUPPORT II Pivotal Trial is a significant positive for the medical device market, particularly for companies developing percutaneous ventricular assist devices. This advancement could lead to improved treatment options for high-risk cardiac patients, potentially expanding the market for such devices in the United States.

Medical Devices Biotechnology Healthcare

Event Summary

Supira Medical, a clinical-stage company, announced FDA approval to initiate its SUPPORT II Pivotal Trial for its next-generation percutaneous ventricular assist device (pVAD). This trial is a crucial step towards U.S. market entry for the device, which aims to transform the pVAD market by offering a smaller profile and improved patient mobility. The study will enroll up to 385 patients across 40 U.S. sites and is co-led by Dr. Ajay Kirtane and Dr. David Kandzari. Additionally, Supira Medical reported advances in treating cardiogenic shock patients outside the U.S. and appointed D. Keith Grossman, a medical device industry veteran, to its Board of Directors to strengthen its commercial foundation and prepare for market growth.

Key Actions

100 United States===Food and Drug Administration approved initiation of pivotal trial Supira Medical

90 Supira Medical initiated SUPPORT II Pivotal Trial

70 Supira Medical appointed to Board of Directors D. Keith Grossman

Entities Involved

priv

Supira Medical

Supira Medical received FDA approval to initiate its SUPPORT II Pivotal Trial for its next-generation pVAD, a critical step towards U.S. market entry. The company also announced advances in treating cardiogenic shock and appointed D. Keith Grossman to its Board of Directors, strengthening its commercial foundation and market readiness.

Importance 100 Sentiment 70

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration granted approval to Supira Medical to initiate the SUPPORT II Pivotal Trial, which is a crucial regulatory step for the company's next-generation pVAD to enter the U.S. market.

Importance 80 Sentiment 0

per

D. Keith Grossman

D. Keith Grossman was appointed to Supira Medical's Board of Directors, bringing 40 years of medical technology industry experience to reinforce the company's focus on scaling and market growth.

Importance 60 Sentiment 0

per

Ajay Kirtane

Ajay Kirtane is a national co-principal investigator for the SUPPORT II Pivotal Trial, emphasizing the importance of the novel pVAD in advancing care for high-risk patients.

Importance 50 Sentiment 0

per

David Kandzari

David Kandzari is a national co-principal investigator for the SUPPORT II Pivotal Trial, highlighting the potential of a smaller profile pVAD to expand treatment options and improve effectiveness in HRPCI.

Importance 50 Sentiment 0

cnt

United States

The United States is the target market for Supira Medical's pVAD, with the SUPPORT II Pivotal Trial being a critical step towards U.S. market entry and involving up to 40 U.S. sites.

Importance 40 Sentiment 0

per

Nitin Salunke

Nitin Salunke, President and CEO of Supira Medical, commented on the appointment of D. Keith Grossman, emphasizing his valuable operational discipline and strategic perspective.

Importance 30 Sentiment 0

+ 1 more entities View on Dashboard

Relationships

David Kandzari related ↔ Piedmont Healthcare

D. Keith Grossman related ↔ Supira Medical

Nitin Salunke related ↔ Supira Medical

Supira Medical related ↔ United States===Food and Drug Administration

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard